This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's
by Zacks Equity Research
Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's are included in this Analyst Blog.
Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), TotalEnergies SE (TTE) and U.S. Bancorp (USB), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks
by Tirthankar Chakraborty
Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy
by Zacks Equity Research
Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
by Sanghamitra Saha
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
by Kinjel Shah
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
by Kinjel Shah
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
by Zacks Equity Research
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
by Zacks Equity Research
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.